<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sacubitril and valsartan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sacubitril and valsartan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sacubitril and valsartan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="103201" href="/d/html/103201.html" rel="external">see "Sacubitril and valsartan: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="126106" href="/d/html/126106.html" rel="external">see "Sacubitril and valsartan: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F28658454"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue sacubitril/valsartan as soon as possible.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28749957"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Entresto</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871958"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Entresto</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28658465"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiotensin II Receptor Blocker;</li>
<li>
                        Neprilysin Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F29038164"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Entresto contains sacubitril and valsartan. To reduce the risk of a prescribing error, include the dose of each component separately (eg, sacubitril 24 mg/valsartan 26 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Valsartan in the combination tablet is more bioavailable than valsartan in other marketed tablet formulations; valsartan 26 mg, 51 mg, and 103 mg in the combination tablet is equivalent to valsartan 40 mg, 80 mg, and 160 mg in other marketed tablet formulations, respectively.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Sacubitril/valsartan is a replacement for an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). Allow a 36-hour washout period when switching from an ACE inhibitor to sacubitril/valsartan. No washout period is necessary for patients previously on an ARB. Consider for use in hemodynamically stable patients with systolic BP ≥100 mm Hg, no increase in IV diuretic dose in the previous 6 hours, no use of an IV vasodilator in the previous 6 hours, no use of an IV inotrope in the previous 24 hours, and serum potassium &lt;5 mEq/L. Monitor volume status and diuretic requirement throughout therapy; may need to reduce loop diuretic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-25176015','lexi-content-ref-30741494','lexi-content-ref-30741494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-25176015','lexi-content-ref-30741494','lexi-content-ref-30741494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients previously taking a moderate to high dose of an ACE inhibitor (eg, &gt;10 mg/day of enalapril or equivalent) or ARB (eg, &gt;160 mg/day of valsartan or equivalent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Sacubitril 49 mg/valsartan 51 mg twice daily. Double the dose as tolerated after ~2 to 4 weeks to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients previously taking a low dose of an ACE inhibitor (eg, ≤10 mg/day of enalapril or equivalent) or ARB (eg, ≤160 mg/day of valsartan or equivalent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Sacubitril 24 mg/valsartan 26 mg twice daily. Double the dose as tolerated in ~2- to 4-week intervals to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients not currently taking an ACE inhibitor or an ARB:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>Initial: Sacubitril 24 mg/valsartan 26 mg twice daily. Double the dose as tolerated in ~2- to 4-week intervals to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f33741f0-04cd-4e33-bc84-7a0dba201c10">Heart failure with preserved ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with preserved ejection fraction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Sacubitril/valsartan is a replacement for an ACE inhibitor or ARB. Administer in place of an ACE inhibitor or ARB. Allow a 36-hour washout period when switching from an ACE inhibitor to sacubitril/valsartan. No washout period is necessary for patients previously on an ARB. Consider for use after optimizing mineralocorticoid-receptor antagonist and sodium-glucose transport protein 2 receptor antagonist therapies, particularly in patients with ejection fraction &lt;55%, patients who remain hypertensive, or who were recently hospitalized for heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Borlaug.2022','lexi-content-ref-31475794','lexi-content-ref-31726194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Borlaug.2022','lexi-content-ref-31475794','lexi-content-ref-31726194'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: Sacubitril 24 mg/valsartan 26 mg twice daily <b>or </b>sacubitril 49 mg/valsartan 51 mg twice daily, depending on baseline BP. Double the dose as tolerated in ~2- to 4-week intervals to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Borlaug.2022','lexi-content-ref-31475794','lexi-content-ref-31726194','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Borlaug.2022','lexi-content-ref-31475794','lexi-content-ref-31726194','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991435"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Exposure to the active metabolite, sacubitrilat, is approximately doubled in patients with eGFR 30 to 60 mL/minute/1.73 m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28417439','lexi-content-ref-27230850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28417439','lexi-content-ref-27230850'])">Ref</a></span>); however, patients with mild to moderate kidney impairment were enrolled in clinical trials without dose adjustment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25176015','lexi-content-ref-31475794','lexi-content-ref-30741494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25176015','lexi-content-ref-31475794','lexi-content-ref-30741494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily. Double the dose as tolerated every 2 to 4 weeks to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg twice daily. <b>Note:</b> Safety and efficacy data are limited in this population, especially at eGFR &lt;20 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30002098','lexi-content-ref-33822031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30002098','lexi-content-ref-33822031'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (valsartan and sacubitril are both highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Recommend dosing as though the patient has an eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Safety and efficacy data are limited in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32153122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32153122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (valsartan and sacubitril are both highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Recommend dosing as though the patient has an eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Safety and efficacy data are limited in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32153122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32153122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Avoid use; no safety and efficacy data are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Avoid use; no safety and efficacy data are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988740"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Initial: Sacubitril 24 mg/valsartan 26 mg twice daily. Should be used with caution in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use not recommended (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F29038165"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53824412"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="126106" href="/d/html/126106.html" rel="external">see "Sacubitril and valsartan: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Entresto is a combination of sacubitril and valsartan. Use extra precautions when dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing for the oral suspension is presented as the combined mg dose of sacubitril and valsartan. Dosing for the oral tablet is presented as the individual mg for each component.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>An oral suspension may be extemporaneously prepared. The sacubitril:valsartan ratio varies slightly with each tablet strength; <b>only </b>the 49/51 mg tablets can be used to compound the oral suspension to achieve a combined sacubitril and valsartan concentration of 4 mg/mL (sacubitril 1.96 mg and valsartan 2.04 mg/mL) (see <b>Extemporaneous Preparations</b>). If switching between oral suspension and tablets, consider available strengths and adjust dose as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> The valsartan in Entresto is more bioavailable than the valsartan in other marketed tablet formulations; valsartan 26 mg, 51 mg, and 103 mg in Entresto is equivalent to valsartan 40 mg, 80 mg, and 160 mg in other marketed tablet formulations, respectively.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63c31e00-c4d3-4824-b527-6cd807315bc1">Heart failure, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure, treatment:</b>
<b>Note:</b> Concomitant use of an angiotensin-converting enzyme (ACE) inhibitor is contraindicated; allow a 36-hour washout period when switching from or to an ACE inhibitor.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients previously taking a moderate to high dose ACE inhibitor (ie, ≥0.2 mg/kg/day or 10 mg/day of enalapril or equivalent) or angiotensin II receptor blocker (ARB):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Oral suspension (see <b>Extemporaneous Preparations</b>): <b>Note:</b> Dose presented as the combined mg dose of sacubitril and valsartan.</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents weighing &lt;40 kg: Oral: Initial: 1.6 mg/kg/dose twice daily; titrate dose in 2 weeks to 2.3 mg/kg/dose twice daily, then 2 weeks later to 3.1 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">40 to &lt;50 kg: Oral: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily; titrate dose in 2 weeks to sacubitril 49 mg/valsartan 51 mg twice daily, then 2 weeks later to sacubitril 72 mg/valsartan 78 mg (three 24/26 mg tablets) twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: Oral: Initial: Sacubitril 49 mg/valsartan 51 mg twice daily; titrate dose in 2 weeks to sacubitril 72 mg/valsartan 78 mg (three 24/26 mg tablets) twice daily, then 2 weeks later to sacubitril 97 mg/valsartan 103 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients </i>
<b>
<i>not</i></b>
<i> currently taking an ACE inhibitor or an ARB </i>
<b>
<i>or</i></b>
<i> previously taking low doses of an ACE inhibitor (ie, 0.1 mg/kg/day or 5 mg/day of enalapril or equivalent) or ARB:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Oral suspension (see <b>Extemporaneous Preparations</b>): <b>Note:</b> Dose presented as the combined mg dose of sacubitril and valsartan.</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents weighing ≤50 kg: Oral: Initial: 0.8 mg/kg/dose twice daily; titrate dose in 2 weeks to 1.6 mg/kg/dose twice daily, then 2 weeks later to 2.3 mg/kg/dose twice daily, then 2 weeks later to 3.1 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Children and Adolescents weighing &gt;50 kg: Oral: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily; titrate dose in 2 weeks to sacubitril 49 mg/valsartan 51 mg twice daily, then 2 weeks later to sacubitril 72 mg/valsartan 78 mg (three 24/26 mg tablets) twice daily, then 2 weeks later to sacubitril 97 mg/valsartan 103 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53824413"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (eGFR ≥30 mL/minute/1.73 m<sup>2</sup>): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>): Initial: Reduce the usual starting dose by 50%, then follow the recommended dose escalation to titrate dose.</p></div>
<div class="block dohp drugH1Div" id="F53824414"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment: Initial: Reduce the usual starting dose by 50%, then follow the recommended dose escalation to titrate dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use not recommended (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56962163"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sacubitril/valsartan may be associated with <b>increased serum creatinine </b>and/or <b>acute kidney injury</b>; increases in serum creatinine occurred less frequently than with angiotensin receptor blocker (ARB) therapy alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25176015','lexi-content-ref-31475794','lexi-content-ref-32960491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25176015','lexi-content-ref-31475794','lexi-content-ref-32960491'])">Ref</a></span>). Increases in serum creatinine secondary to ARBs usually stabilize within 20% to 30% from baseline and are expected; additional increases may indicate renal artery stenosis, volume depletion, or other explanations for kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; ARBs inhibit efferent renal arteriolar vasoconstriction, lowering glomerular filtration pressure which can lead to a modest reduction in glomerular filtration rate (GFR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10619572'])">Ref</a></span>). Neprilysin inhibition may increase renal natriuretic peptide bioavailability, leading to preserved kidney function, which could explain less frequent increases in serum creatinine with combination ARB and neprilysin inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32960491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32960491'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Expected to be similar to angiotensin-converting enzyme inhibitors: Intermediate; transient increases in serum creatinine generally occur within 2 weeks of ARB initiation and stabilize within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10724055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10724055'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (ARB):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Sodium or volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic or nonsteroidal anti-inflammatory drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with low renal blood flow (eg, renal artery stenosis) whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema </b>has been reported with sacubitril/valsartan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32841619','lexi-content-ref-34125356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32841619','lexi-content-ref-34125356'])">Ref</a></span>). Although most reported cases are mild, some patients may require hospitalization including mechanical airway support (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28452844','lexi-content-ref-29776559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28452844','lexi-content-ref-29776559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; likely related to pharmacologic action. Inhibitors of neprilysin may increase bradykinin levels or block breakdown of A-type natriuretic peptide, and combination with valsartan may cause bradykinin overactivation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483314'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; similar to angioedema associated with angiotensin-converting enzyme inhibitors (ACEI) onset may occur at any time during treatment and may be significantly delayed. Cases have been reported during the first week of therapy but may also occur months to years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32841619','lexi-content-ref-29776559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32841619','lexi-content-ref-29776559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased risk of angioedema with sacubitril/valsartan compared with angiotensin receptor blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33459086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33459086'])">Ref</a></span>); similar risk with ACEIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32841619','lexi-content-ref-28720639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32841619','lexi-content-ref-28720639'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Black patients (similar to ACEIs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28720639','lexi-content-ref-29776559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28720639','lexi-content-ref-29776559'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use with ACEI (contraindicated); sacubitril/valsartan should not be administered within 36 hours of switching from or to an ACEI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of angioedema (contraindicated regardless of cause according to guidelines); risk is unknown, as patients with a history of angioedema were excluded from studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27208050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27208050'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia </b>may occur; however, studies have shown lower incidence of severe hyperkalemia than with angiotensin receptor blocker (ARB) therapy alone; neprilysin inhibition may attenuate hyperkalemia risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842179','lexi-content-ref-25176015','lexi-content-ref-31475794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842179','lexi-content-ref-25176015','lexi-content-ref-31475794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; ARBs inhibit angiotensin II from binding to the adrenal receptor and interferes with generation of angiotensin II within the adrenal cortex, decreasing aldosterone release and impairing renal potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1855477','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1855477','lexi-content-ref-21883995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Generally occurs within 1 week of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24262001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24262001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High dietary intake of potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevated potassium (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842179','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842179','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842179','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842179','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher NYHA heart failure class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher natriuretic peptide levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoaldosteronism</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications known to decrease renin and aldosterone (eg, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, cyclosporine, tacrolimus, beta-blockers, sulfamethoxazole/trimethoprim, azole antifungals) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20585070','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20585070','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-27842179','lexi-content-ref-15295051'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension </b>may occur during therapy initiation and occurs at a higher rate than with angiotensin receptor blocker (ARB) therapy alone. Proactive reduction in diuretic dose or initiation at a lower dose may be required; therapy discontinuation is generally not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-25176015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-25176015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Inhibition of the renin-angiotensin system and enhanced activity of natriuretic peptides leads to blood pressure lowering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30565021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30565021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; however, delayed onset of up to 18 hours has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29375230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29375230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33931815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33931815'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid versus gradual titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27170530','lexi-content-ref-29164797','lexi-content-ref-30741494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27170530','lexi-content-ref-29164797','lexi-content-ref-30741494'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antihypertensives</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic (or otherwise hypovolemic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29643067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29643067'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower baseline blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28158398','lexi-content-ref-29164797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28158398','lexi-content-ref-29164797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29643067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29643067'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• ICD present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29643067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29643067'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F29112604"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults; adverse reactions in children and adolescents are consistent with those in adults. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (18%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension" frame="border" id="lexi-content-hypotension" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (12%)<span class="lexi-table-link-container"> (<a aria-label="Hyperkalemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperkalemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperkalemia')">table 2</a>)</span><span class="table-link" style="display:none;">Hyperkalemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperkalemia" frame="border" id="lexi-content-hyperkalemia" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Hyperkalemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (16% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Creatinine table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-creatinine" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-creatinine')">table 3</a>)</span><span class="table-link" style="display:none;">Increased Serum Creatinine</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Creatinine" frame="border" id="lexi-content-increased-serum-creatinine" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Increased Serum Creatinine</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Valsartan: 21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,407</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,389</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increases in serum creatinine of &gt;50%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Enalapril: 16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increases in serum creatinine of &gt;50%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (2%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 4</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (≤7%), decreased hemoglobin (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Black patients: 2%; others: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Angioedema table link" class="lexi-table-link" data-table-id="lexi-content-angioedema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-angioedema')">table 5</a>)</span><span class="table-link" style="display:none;">Angioedema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Angioedema" frame="border" id="lexi-content-angioedema" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Angioedema</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Black adult patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adult patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (6%), falling (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (≤5%)<span class="lexi-table-link-container"> (<a aria-label="Acute Kidney Injury table link" class="lexi-table-link" data-table-id="lexi-content-acute-kidney-injury" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-acute-kidney-injury')">table 6</a>)</span><span class="table-link" style="display:none;">Acute Kidney Injury</span>, renal failure syndrome (≤5%)<span class="lexi-table-link-container"> (<a aria-label="Renal Failure Syndrome table link" class="lexi-table-link" data-table-id="lexi-content-renal-failure-syndrome" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-renal-failure-syndrome')">table 7</a>)</span><span class="table-link" style="display:none;">Renal Failure Syndrome</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Acute Kidney Injury" frame="border" id="lexi-content-acute-kidney-injury" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Acute Kidney Injury</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "renal failure/acute renal failure"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Renal Failure Syndrome" frame="border" id="lexi-content-renal-failure-syndrome" rules="all">
<caption style="text-align:center;">
<b>Sacubitril and Valsartan: Adverse Reaction: Renal Failure Syndrome</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacubitril and Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Enalapril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,229</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "renal failure/acute renal failure"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F28658457"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sacubitril, valsartan, or any component of the formulation; history of angioedema related to previous ACE inhibitor or ARB therapy; concomitant use or use within 36 hours of ACE inhibitors; concomitant use of aliskiren in patients with diabetes</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> According to the ACC/AHA/HFSA guidelines, the use of sacubitril/valsartan is contraindicated in patients with a history of angioedema, regardless of cause (AHA/ACC/HFSA [Heidenreich 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Recent symptomatic hypotension prior to initiation of treatment with sacubitril/valsartan; concomitant use of aliskiren in patients with moderate to severe kidney impairment (eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>); pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F29037672"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy, because of hypotension. Careful monitoring of BUN, serum creatinine, and potassium is necessary especially if preexisting kidney disease exists.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution and reduce dosage in patients with moderate hepatic impairment; use is not recommended in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in preexisting kidney insufficiency; dose adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients on chronic angiotensin receptor blocker (ARB) therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011).</p></div>
<div class="block foc drugH1Div" id="F28749958"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entresto: Sacubitril 24 mg and valsartan 26 mg, Sacubitril 49 mg and valsartan 51 mg, Sacubitril 97 mg and valsartan 103 mg</p></div>
<div class="block geq drugH1Div" id="F28749956"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F29835910"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Entresto Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24-26 mg (per each): $13.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">49-51 mg (per each): $13.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">97-103 mg (per each): $13.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871959"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entresto: Sacubitril 24 mg and valsartan 26 mg, Sacubitril 49 mg and valsartan 51 mg, Sacubitril 97 mg and valsartan 103 mg</p></div>
<div class="block adm drugH1Div" id="F29038169"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food.</p></div>
<div class="block admp drugH1Div" id="F53824415"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. If switching between oral suspension and tablets, consider available strengths and adjust dose as needed.</p></div>
<div class="block use drugH1Div" id="F28658456"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adult: Reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in patients with chronic HF. Benefits are most clearly evident in patients with left ventricular ejection fraction below normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric: Treatment of symptomatic HF with systemic left ventricular systolic dysfunction in pediatric patients ≥1 year of age.</p></div>
<div class="block mst drugH1Div" id="F56413138"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28843360"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F28843357"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Receptor Blockers may diminish the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Valsartan. Management: Consider decreasing the valsartan dose and monitoring for evidence of hypotension and worsening renal function if these agents are used in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Sacubitril may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F29037670"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">
<b>[US Boxed Warning]: Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue sacubitril/valsartan as soon as possible.</b> Refer to the valsartan monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F29037671"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if sacubitril or valsartan is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F29038171"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">At baseline, within 1 to 2 weeks after initiation, and after dose changes, reassess BP (including postural BP changes), kidney function, and serum potassium (especially for patients taking concomitant potassium-sparing diuretics, potassium supplements, and/or potassium containing salts). Patients with systolic BP &lt;80 mm Hg, low serum sodium, diabetes mellitus, and impaired kidney function should be closely monitored.</p></div>
<div class="block pha drugH1Div" id="F29037675"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Sacubitril: Prodrug that inhibits neprilysin (neutral endopeptidase) through the active metabolite LBQ657, leading to increased levels of peptides, including natriuretic peptides; induces vasodilation and natriuresis (Hubers 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Valsartan: Produces direct antagonism of the angiotensin II (AT2) receptors. Displaces angiotensin II from the AT1 receptor; antagonizes AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses.</p></div>
<div class="block phk drugH1Div" id="F29037677"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Sacubitril: 103 L; Valsartan: 75 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94% to 97%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;">Sacubitril: Converted to active metabolite LBQ657 by esterases; LBQ657 is not further metabolized to a significant extent</p>
<p style="text-indent:-2em;margin-left:4em;">Valsartan: Minimally metabolized (~20%; &lt;10% as a hydroxyl metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Sacubitril: ≥60%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Sacubitril: 1.4 hours; LBQ657: 11.5 hours; Valsartan: 9.9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Sacubitril: 0.5 hours; LBQ657: 2 hours; Valsartan: 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Sacubitril: Urine (52% to 68%, primarily as LBQ657); feces (37% to 48%, primarily as LBQ657)</p>
<p style="text-indent:-2em;margin-left:4em;">Valsartan: Urine (~13%, parent drug and metabolites); feces (86%, parent drug and metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45784030"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dupertan | Entresto | Hiperval plus | Neparvis | Ristonel</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arnigen | Sabitar | Vivanta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Sacubitril valsartan sodium</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Valsartec plus | Vymada</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Uperio</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Uperio</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Arney | Arnicor | Arnipin | Arniv | Arnoza | Arnx | Azmarda | Cidmus | Exduo | Hefcard | Mymarda | Neptaz | Refsav | Sacurise | Sacutan | Valentas | Valsac | Vymada | Zayo</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Diotril</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Uperio</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Xnepri</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Uperio</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Vymada</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cubil | Sacuval | Sacuvia | Sacvin | Savesto | Uperio | Valsar s | Valsatril</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Neparvis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diusartan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Entresto | Uperio</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Oneptus</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Uperio</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Entresto</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20585070">
<a name="20585070"></a>Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. doi:10.1001/archinternmed.2010.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/20585070/pubmed" id="20585070" target="_blank">20585070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28417439">
<a name="28417439"></a>Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. <i>Clin Pharmacokinet</i>. 2017;56(12):1461-1478. doi:10.1007/s40262-017-0543-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/28417439/pubmed" id="28417439" target="_blank">28417439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27230850">
<a name="27230850"></a>Ayalasomayajula SP, Langenickel TH, Jordaan P, et al. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. <i>Eur J Clin Pharmacol</i>. 2016;72(9):1065-1073. doi:10.1007/s00228-016-2072-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/27230850/pubmed" id="27230850" target="_blank">27230850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10724055">
<a name="10724055"></a>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? <i>Arch Intern Med</i>. 2000;160(5):685-693. doi:10.1001/archinte.160.5.685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/10724055/pubmed" id="10724055" target="_blank">10724055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28158398">
<a name="28158398"></a>Böhm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>Eur Heart J</i>. 2017;38(15):1132-1143. doi:10.1093/eurheartj/ehw570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/28158398/pubmed" id="28158398" target="_blank">28158398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Borlaug.2022">
<a name="Borlaug.2022"></a>Borlaug BA, Colucci WS. Treatment and prognosis of heart failure with preserved ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32841619">
<a name="32841619"></a>Dani SS, Ganatra S, Vaduganathan M. Angioedema with sacubitril/valsartan: trial-level meta-analysis of over 14,000 patients and real-world evidence to date. <i>Int J Cardiol</i>. 2021;323:188-191. doi:10.1016/j.ijcard.2020.08.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/32841619/pubmed" id="32841619" target="_blank">32841619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17996561">
<a name="17996561"></a>Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. <i>J Am Coll Cardiol</i>. 2007;50(20):1959-1966. doi:10.1016/j.jacc.2007.07.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/17996561/pubmed" id="17996561" target="_blank">17996561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27842179">
<a name="27842179"></a>Desai AS, Vardeny O, Claggett B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. <i>JAMA Cardiol</i>. 2017;2(1):79-85. doi:10.1001/jamacardio.2016.4733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/27842179/pubmed" id="27842179" target="_blank">27842179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drazner.2019">
<a name="Drazner.2019"></a>Drazner M. Use of angiotensin receptor-neprilysin inhibitor in heart failure with reduced ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/use-of-angiotensin-receptor-neprilysin-inhibitor-in-heart-failure-with-reduced-ejection-fraction?search=use%20of%20angiotensin%20receptor-neprilysin%20inhibitor&amp;source=search_result&amp;selectedTitle=1~43&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed January 31, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Entresto.1">
<a name="Entresto.1"></a>Entresto (sacubitril/valsartan) [dosing and titration guide]. East Hanover, NJ: Novartis; November 2015. https://www.entrestohcp.com/sfc/servlet.shepherd/version/download/06812000001NqWHAA0.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Entresto.2">
<a name="Entresto.2"></a>Entresto (sacubitril/valsartan) [prescribing information]. East Hanover, NJ: Novartis; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Entresto.3">
<a name="Entresto.3"></a>Entresto (sacubitril/valsartan) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30002098">
<a name="30002098"></a>Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. <i>Circulation</i>. 2018;138(15):1505-1514. doi:10.1161/CIRCULATIONAHA.118.034818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/30002098/pubmed" id="30002098" target="_blank">30002098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124:2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29375230">
<a name="29375230"></a>Hsiao FC, Chu PH. Prolonged first-dose hypotension induced by sacubitril/valsartan. <i>Acta Cardiol Sin</i>. 2018;34(1):96-98. doi:10.6515/ACS.201801_34(1).20170614A<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/29375230/pubmed" id="29375230" target="_blank">29375230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976916">
<a name="26976916"></a>Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. <i>Circulation</i>. 2016;133(11):1115-1124. doi: 10.1161/CIRCULATIONAHA.115.018622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/26976916/pubmed" id="26976916" target="_blank">26976916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28483314">
<a name="28483314"></a>Hudey SN, Westermann-Clark E, Lockey RF. Cardiovascular and diabetic medications that cause bradykinin-mediated angioedema. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):610-615. doi:10.1016/j.jaip.2017.03.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/28483314/pubmed" id="28483314" target="_blank">28483314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>ISMP. FDA Advise-ERR: concomitant use of entresto and ACE inhibitors can lead to serious outcome<i>s</i>. January 12, 2017. Available at https://www.ismp.org/resources/fda-advise-err-concomitant-use-entresto-and-ace-inhibitors-can-lead-serious-outcomes#:~:text=Entresto%20is%20contraindicated%20with%20concomitant,increases%20the%20risk%20of%20angioedema
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/ISMP.1/pubmed" id="ISMP.1" target="_blank">ISMP.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease Improving Global Outcomes (KDIGO). 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl</i>. 2013;3(suppl 1):1-150. http://www.kidney-international.org.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/KDIGO.1/pubmed" id="KDIGO.1" target="_blank">KDIGO.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1855477">
<a name="1855477"></a>Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. <i>Endocrinology</i>. 1991;129(2):823-831. doi:10.1210/endo-129-2-823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/1855477/pubmed" id="1855477" target="_blank">1855477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34125356">
<a name="34125356"></a>Kim YS, Brar S, D'Albo N, et al. Five years of sacubitril/valsartan-a safety analysis of randomized clinical trials and real-world pharmacovigilance. <i>Cardiovasc Drugs Ther</i>. 2021. doi:10.1007/s10557-021-07210-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/34125356/pubmed" id="34125356" target="_blank">34125356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23176216">
<a name="23176216"></a>Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. <i>Curr Pharm Des</i>. 2013;19(17):3033-3042. doi:10.2174/1381612811319170009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/23176216/pubmed" id="23176216" target="_blank">23176216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32153122">
<a name="32153122"></a>Lee S, Oh J, Kim H, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. <i>ESC Heart Fail.</i> 2020;7(3):1125-1129. doi:10.1002/ehf2.12659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/32153122/pubmed" id="32153122" target="_blank">32153122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33446410">
<a name="33446410"></a>Maddox TM, Januzzi JL Jr, Allen LA, et al; Writing Committee. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/33446410/pubmed" id="33446410" target="_blank">33446410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33459086">
<a name="33459086"></a>Martins E Pereira G, S Duarte G, Katerenchuk V, et al. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. <i>Expert Opin Drug Saf</i>. 2021;20(5):577-588. doi:10.1080/14740338.2021.1877658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/33459086/pubmed" id="33459086" target="_blank">33459086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25176015">
<a name="25176015"></a>McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med</i>. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/25176015/pubmed" id="25176015" target="_blank">25176015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33931815">
<a name="33931815"></a>Ntalianis A, Chrysohoou C, Giannakoulas G, et al. Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. <i>Heart Fail Rev</i>. 2022;27(1):1-13. doi:10.1007/s10741-021-10115-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/33931815/pubmed" id="33931815" target="_blank">33931815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28720639">
<a name="28720639"></a>Owens RE, Oliphant CS. Angioedema spotlight: a closer examination of sacubitril/valsartan safety results. <i>J Am Board Fam Med</i>. 2017;30(4):556-557. doi:10.3122/jabfm.2017.04.170111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/28720639/pubmed" id="28720639" target="_blank">28720639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24262001">
<a name="24262001"></a>Park IW, Sheen SS, Yoon D, et al. Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring? <i>J Clin Pharm Ther</i>. 2014;39(1):61-68. doi:10.1111/jcpt.12109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/24262001/pubmed" id="24262001" target="_blank">24262001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33822031">
<a name="33822031"></a>Pontremoli R, Borghi C, Filardi PP. Renal protection in chronic heart failure: focus on sacubitril/valsartan. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2021:pvab030. doi:10.1093/ehjcvp/pvab030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/33822031/pubmed" id="33822031" target="_blank">33822031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28452844">
<a name="28452844"></a>Raheja H, Kumar V, Kamholz S, Hollander G, Shani J. Life threatening angioedema due to valsartan/sacubitril with previously well-tolerated ACE inhibitor. <i>Am J Ther</i>. 2018;25(4):e508-e509. doi:10.1097/MJT.0000000000000600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/28452844/pubmed" id="28452844" target="_blank">28452844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30618189">
<a name="30618189"></a>Rasmussen ER, Pottegård A, Bygum A, von Buchwald C, Homøe P, Hallas J. Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study. <i>J Intern Med</i>. 2019;285(5):553-561. doi:10.1111/joim.12867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/30618189/pubmed" id="30618189" target="_blank">30618189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695383">
<a name="18695383"></a>Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury? <i>Curr Opin Nephrol Hypertens</i>. 2008;17(5):443-449. doi:10.1097/MNH.0b013e32830a9606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/18695383/pubmed" id="18695383" target="_blank">18695383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30565021">
<a name="30565021"></a>Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. <i>Heart Fail Rev</i>. 2019;24(2):167-176. doi:10.1007/s10741-018-9757-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/30565021/pubmed" id="30565021" target="_blank">30565021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29164797">
<a name="29164797"></a>Senni M, McMurray JJV, Wachter R, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>Eur J Heart Fail</i>. 2018;20(3):491-500. doi:10.1002/ejhf.1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/29164797/pubmed" id="29164797" target="_blank">29164797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27170530">
<a name="27170530"></a>Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>Eur J Heart Fail</i>. 2016;18(9):1193-1202. doi:10.1002/ejhf.548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/27170530/pubmed" id="27170530" target="_blank">27170530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29129252">
<a name="29129252"></a>Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). <i>Am Heart J</i>. 2017;193:23-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/29129252/pubmed" id="29129252" target="_blank">29129252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29776559">
<a name="29776559"></a>Shi V, Senni M, Streefkerk H, Modgill V, Zhou W, Kaplan A. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. <i>Int J Cardiol</i>. 2018;264:118-123. doi:10.1016/j.ijcard.2018.03.121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/29776559/pubmed" id="29776559" target="_blank">29776559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31475794">
<a name="31475794"></a>Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. <i>N Engl J Med</i>. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/31475794/pubmed" id="31475794" target="_blank">31475794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32960491">
<a name="32960491"></a>Spannella F, Giulietti F, Filipponi A, Sarzani R. Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. <i>ESC Heart Fail</i>. 2020;7(6):3487-3496. doi:10.1002/ehf2.13002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/32960491/pubmed" id="32960491" target="_blank">32960491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147456">
<a name="23147456"></a>Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. <i>Arch Intern Med</i>. 2012;172(20):1582-1589. doi:10.1001/2013.jamainternmed.34<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/23147456/pubmed" id="23147456" target="_blank">23147456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31726194">
<a name="31726194"></a>Vaduganathan M, Claggett BL, Desai AS, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. <i>J Am Coll Cardiol</i>. 2020;75(3):245-254. doi:10.1016/j.jacc.2019.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/31726194/pubmed" id="31726194" target="_blank">31726194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29643067">
<a name="29643067"></a>Vardeny O, Claggett B, Kachadourian J, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circ Heart Fail</i>. 2018;11(4):e004745. doi:10.1161/CIRCHEARTFAILURE.117.004745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/29643067/pubmed" id="29643067" target="_blank">29643067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30741494">
<a name="30741494"></a>Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>Eur J Heart Fail</i>. 2019;21(3):337-341. doi:10.1002/ejhf.1402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/30741494/pubmed" id="30741494" target="_blank">30741494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30741494">
<a name="30741494"></a>Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. <i>N Engl J Med</i>. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/30741494/pubmed" id="30741494" target="_blank">30741494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27208050">
<a name="27208050"></a>Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. <i>Circulation</i>. 2016;134(13):e282-e293. doi:10.1161/CIR.0000000000000435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacubitril-and-valsartan-drug-information/abstract-text/27208050/pubmed" id="27208050" target="_blank">27208050</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 102505 Version 194.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
